ABOUT USABOUT US
Nanjing Aureole Pharmaceutical Co.,Ltd
Established in October 12, 2017 in Nanjing City where is the ancient capital of six dynasties, Aureole, with a total registered investment capital of 100 million Chinese Yuan, is a high-tech enterprise specialized in R&D, manufacturing and sale of the sterilized inhalation product and eyedrops with an international development strategy. Our R&D specialists accouts for 30% of the total 120 employees and more than 86% employees owns the bachelor degree.
MoreProductsProducts
CDMOCDMO
-
Formulation Development
We have strong capabilities to provide CRO and CMO to our customer in inhalation products ,eye drops products, solid preparations, injection products and health care products. Thanks to the first-rate BFS system and various advanced testing equipment, we could provide reverse engineering for initial reference, drug substance screening, and a turnkey service from laboratory process optimization to pilot production, especially for inhalation and eye drops product.More -
Pharmaceutical Analysis
Our labs are constructed in accordance with the GLP standard of China, Europe and America, and managed with the LIMS system which is an industry well-recognized laboratory information management system. We could provide GMP qualitative and quantitative analysis service and stability research on drug substance, excipients, package, and intermediates to our customer.More -
Drug Registration
Our product registration department could provide registration service for IND, NDA and ANDA in China, EU and USA, and consulting service in certain countries and regions.More -
Single Dosage Sterilized Preparation Manufacturing
Equipped with the first-rate Rommelag BFS system, We produce single dosage sterilized inhalation preparation and eyedrops developed by our own team. And we have capacities and capabilities to provide those kind CMO service to our customer. We warmly welcome your visit and negotiate.More
News & EventsNews
Congratulations to Our Company on the Approval of a New Specification for Procaterol Hydrochloride Inhalation Solution, Including Pediatric Indications for Both Specifications
On September 24, 2024, our 0.3 mL specification of Procaterol Hydrochloride Inhalation Solution received production approval from the National Medical Products Administration (NMPA), alongside the 0.5 mL specification. Both specifications were approved for pediatric indications. Procaterol H
More